IMAB I-Mab - ADR

$IMAB Potential big catalyst at ESMO 2026 this month! Phase 1b results, if same as previous results will de-risk Givastomig and add value to NBP. Second catalyst accelerated Phase III. ESMO 2026 Presentation Details: • Event: European Society for Medical Oncology (ESMO) Congress 2026 • Dates: October 23–27, 2026 • Presentation Date: October 25, 2026 • Location: Madrid, Spain Study & Drug Focus: • Drug: Givastomig (a potential first-in-class Claudin 18.2 × 4-1BB bispecific antibody / Claudin 18.2-Targeted Immuno Amplifier) • Combination Regimen: Givastomig combined with nivolumab and chemotherapy (mFOLFOX6) Program Context: • FDA Status: Granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for untreated advanced/metastatic GEA in combination with nivolumab and chemotherapy. • Next Steps: A global, randomized Phase 2 study is underway, with a Phase 3 registrational study under a potential Accelerated Approval Pathway anticipated as early as the end of 2026.

$IMAB ESMO 2026 Givastomig Phase 1b results will be announced October 25th. Could be a big catalyst if positive.